InsiderTrades.com logo
The latest trend in real estate
From Pacaso   |   Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.

ZURA Insider Trading

Insider Ownership Percentage: 22.10%
Insider Buying (Last 12 Months): $1,030,998.38
Insider Selling (Last 12 Months): $2,934,645.45

Zura Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Zura Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zura Bio Share Price & Price History

Current Price: $3.00
Price Change: ▼ Price Decrease of -0.01 (-0.33%)
As of 11/27/2024 01:00 AM ET

This chart shows the closing price history over time for ZURA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
URGENT: Black Friday Flash Sale! (95% Off)
From Behind the Markets   |   Ad
For the first time this year, we're allowing you to unlock a lifetime subscription to Behind the Markets and receive 6 exclusive reports at the biggest discount we've ever given. In the past year, Behind the Markets subscribers saw an average of 57.54% in returns.
Get LIFETIME ACCESS to Behind the Markets for $99 here >>>

Zura Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2024Parvinder ThiaraDirectorSell1,001,633$2.73$2,734,458.09View SEC Filing Icon  
9/4/2024Someit SidhuDirectorSell51,728$3.87$200,187.362,085,418View SEC Filing Icon  
5/17/2024Van Amstel Arnout PloosDirectorBuy80,000$6.20$496,000.00100,000View SEC Filing Icon  
4/22/2024Amit MunshiDirectorBuy159,744$3.13$499,998.72777,384View SEC Filing Icon  
4/22/2024Kiran NistalaEVPBuy3,195$3.13$10,000.353,195View SEC Filing Icon  
4/22/2024Michael HowellInsiderBuy7,987$3.13$24,999.317,987View SEC Filing Icon  
6/5/2023Amit MunshiDirectorBuy117,647$4.25$499,999.75617,640View SEC Filing Icon  
See Full Table
URGENT: Black Friday Flash Sale! (95% Off)
From Behind the Markets   |   Ad
For the first time this year, we're allowing you to unlock a lifetime subscription to Behind the Markets and receive 6 exclusive reports at the biggest discount we've ever given. In the past year, Behind the Markets subscribers saw an average of 57.54% in returns.
Get LIFETIME ACCESS to Behind the Markets for $99 here >>>

SEC Filings (Institutional Ownership Changes) for Zura Bio (NASDAQ:ZURA)

61.14% of Zura Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ZURA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Zura Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/19/2024Barclays PLC64,061$0.26M0.0%+777.1%0.098%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC912,625$3.71M0.0%+70.6%1.358%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC64,061$0.26M0.0%+777.1%0.095%Search for SEC Filing on Google Icon
11/15/2024Sphera Funds Management LTD.738,718$3M0.5%N/A1.099%Search for SEC Filing on Google Icon
11/15/2024State Street Corp395,059$1.60M0.0%+47.5%0.588%Search for SEC Filing on Google Icon
11/14/2024Braidwell LP2,472,806$10.04M0.3%N/A3.679%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC27,260$0.11M0.0%N/A0.041%Search for SEC Filing on Google Icon
11/14/2024Healthcare of Ontario Pension Plan Trust Fund11,250$46K0.0%N/A0.017%Search for SEC Filing on Google Icon
11/13/2024Great Point Partners LLC3,263,672$13.25M3.9%-29.7%4.856%Search for SEC Filing on Google Icon
11/13/2024The Manufacturers Life Insurance Company 17,442$71K0.0%N/A0.026%Search for SEC Filing on Google Icon
11/12/2024Valence8 US LP17,495$71K0.0%N/A0.026%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.291,807$1.19M0.0%+51.3%0.434%Search for SEC Filing on Google Icon
10/28/2024Palumbo Wealth Management LLC38,335$0.16M0.1%N/A0.057%Search for SEC Filing on Google Icon
10/3/2024SG Americas Securities LLC15,177$62K0.0%N/A0.035%Search for SEC Filing on Google Icon
8/19/2024Point72 Asset Management L.P.2,413,127$8.45M0.0%N/A5.535%Search for SEC Filing on Google Icon
8/16/2024Forefront Analytics LLC41,569$0.15M0.1%+22.1%0.095%Search for SEC Filing on Google Icon
8/15/2024AQR Capital Management LLC12,319$43K0.0%N/A0.028%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC2,524,000$8.83M0.1%+53.2%5.790%Search for SEC Filing on Google Icon
8/15/2024Affinity Asset Advisors LLC223,335$0.78M0.1%-50.4%0.512%Search for SEC Filing on Google Icon
8/14/2024Great Point Partners LLC4,642,241$16.25M3.1%+68.3%10.649%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC17,400$61K0.0%+51.3%0.040%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp47,109$0.17M0.0%+15.8%0.074%Search for SEC Filing on Google Icon
5/15/2024Affinity Asset Advisors LLC450,009$1.16M0.1%N/A1.044%Search for SEC Filing on Google Icon
2/15/2024Forefront Analytics LLC21,229$99K0.0%+46.8%0.049%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC1,824,000$8.52M0.1%+15.4%4.233%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC1,580,000$10.43M0.2%+66.3%3.667%Search for SEC Filing on Google Icon
11/14/2023Lynx1 Capital Management LP9,917$65K0.0%N/A0.023%Search for SEC Filing on Google Icon
11/13/2023Eisler Capital US LLC100,000$0.66M0.0%N/A0.232%Search for SEC Filing on Google Icon
11/13/2023Silverarc Capital Management LLC404,040$2.67M0.8%+152.5%0.938%Search for SEC Filing on Google Icon
11/8/2023Forefront Analytics LLC14,464$95K0.1%N/A0.034%Search for SEC Filing on Google Icon
10/24/2023Bank of New York Mellon Corp33,973$0.22M0.0%N/A0.079%Search for SEC Filing on Google Icon
10/24/2023Raymond James & Associates77,356$0.51M0.0%+14.0%0.180%Search for SEC Filing on Google Icon
8/15/2023Silverarc Capital Management LLC160,000$1.31M0.4%N/A0.591%Search for SEC Filing on Google Icon
8/15/2023Suvretta Capital Management LLC2,850,000$23.37M1.2%N/A10.536%Search for SEC Filing on Google Icon
8/14/2023Great Point Partners LLC3,295,000$27.02M5.3%N/A12.181%Search for SEC Filing on Google Icon
8/14/2023Deep Track Capital LP2,523,000$20.69M1.0%N/A5.855%Search for SEC Filing on Google Icon
8/10/2023Monashee Investment Management LLC240,000$1.97M0.5%N/A0.887%Search for SEC Filing on Google Icon
8/4/2023American International Group Inc.3,649$30K0.0%N/A0.013%Search for SEC Filing on Google Icon
7/25/2023Raymond James & Associates67,875$0.56M0.0%N/A0.251%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Zura Bio logo
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Read More on Zura Bio

Today's Range

Now: $3.00
Low: $2.92
High: $3.06

50 Day Range

MA: $4.12
Low: $2.73
High: $4.92

52 Week Range

Now: $3.00
Low: $2.00
High: $6.35

Volume

252,387 shs

Average Volume

327,489 shs

Market Capitalization

$195.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Who are the company insiders with the largest holdings of Zura Bio?

Zura Bio's top insider shareholders include:
  1. Someit Sidhu (Director)
  2. Amit Munshi (Director)
  3. Van Amstel Arnout Ploos (Director)
  4. Michael Howell (Insider)
  5. Kiran Nistala (EVP)
  6. Parvinder Thiara (Director)
Learn More about top insider investors at Zura Bio.

Who are the major institutional investors of Zura Bio?

Zura Bio's top institutional investors include:
  1. Great Point Partners LLC — 4.86%
  2. Braidwell LP — 3.68%
  3. Geode Capital Management LLC — 1.36%
  4. Sphera Funds Management LTD. — 1.10%
  5. State Street Corp — 0.59%
  6. Charles Schwab Investment Management Inc. — 0.43%
Learn More about top institutional investors of Zura Bio stock.

Which institutional investors are selling Zura Bio stock?

During the last quarter, ZURA stock was sold by these institutional investors:
  1. Great Point Partners LLC
Within the last year, company insiders that have sold Zura Bio company stock include:
  1. Someit Sidhu (Director)
  2. Amit Munshi (Director)
Learn More investors selling Zura Bio stock.

Which institutional investors are buying Zura Bio stock?

In the last quarter, ZURA stock was bought by institutional investors including:
  1. Braidwell LP
  2. Sphera Funds Management LTD.
  3. Geode Capital Management LLC
  4. State Street Corp
  5. Charles Schwab Investment Management Inc.
  6. Barclays PLC
  7. Barclays PLC
  8. Palumbo Wealth Management LLC
Within the last year, these company insiders have bought Zura Bio stock:
  1. Someit Sidhu (Director)
  2. Amit Munshi (Director)
  3. Van Amstel Arnout Ploos (Director)
  4. Michael Howell (Insider)
Learn More investors buying Zura Bio stock.
The latest trend in real estate
From Pacaso   |   Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.